Mga Batayang Estadistika
| LEI | 5299001RBS9GK9STN379 |
| CIK | 896262 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Amedisys, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 25, 2025 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its |
|
| August 14, 2025 |
As filed with the Securities and Exchange Commission on August 14, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 14, 2025 Registration Statement File No. |
|
| August 14, 2025 |
As filed with the Securities and Exchange Commission on August 14, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 14, 2025 Registration Statement File No. |
|
| August 14, 2025 |
As filed with the Securities and Exchange Commission on August 14, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 14, 2025 Registration Statement File No. |
|
| August 14, 2025 |
As filed with the Securities and Exchange Commission on August 14, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 14, 2025 Registration Statement File No. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3131700 (State or other jurisdiction of incorporation |
|
| August 14, 2025 |
As filed with the Securities and Exchange Commission on August 14, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 14, 2025 Registration Statement File No. |
|
| August 14, 2025 |
As filed with the Securities and Exchange Commission on August 14, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 14, 2025 Registration Statement File No. |
|
| August 14, 2025 |
As filed with the Securities and Exchange Commission on August 14, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 14, 2025 Registration Statement File No. |
|
| August 14, 2025 |
amed-form25 |
|
| August 14, 2025 |
amed-form25 |
|
| August 14, 2025 |
BYLAWS OF Amedisys, Inc. (Effective as of August 14, 2025) Article I OFFICES, CORPORATE SEAL Exhibit 3.2 BYLAWS OF Amedisys, Inc. (Effective as of August 14, 2025) Article I OFFICES, CORPORATE SEAL Section 1.01. Registered Office. The registered office of the corporation in Delaware shall be that set forth in the Certificate of Incorporation or in the most recent amendment of the Certificate of Incorporation or in a certificate filed with the Secretary of State of Delaware changing the re |
|
| August 14, 2025 |
As filed with the Securities and Exchange Commission on August 14, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 14, 2025 Registration Statement File No. |
|
| August 14, 2025 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AmedIsYs, Inc. ARTICLE One Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AmedIsYs, Inc. ARTICLE One The name of the corporation is Amedisys, Inc. (hereinafter called the “Corporation”). ARTICLE Two The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle County, Delaware 19801. The name of its registered agent at suc |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation) (IR |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, INC |
|
| July 29, 2025 |
1 Amedisys Second Quarter 2025 Earnings Release Supplemental Slides July 29, 2025 EXHIBIT 99. |
|
| July 29, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 29, 2025 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporation o |
|
| July 29, 2025 |
AMEDISYS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Exhibit 99.1 AMEDISYS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS BATON ROUGE, Louisiana (July 29, 2025) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2025. Three-Month Periods Ended June 30, 2025 and 2024 •Net service revenue increased $30.7 million to $621.9 million compared to $591.2 million in 2024. •Net income attribu |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation) (IR |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2 ) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0- |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, IN |
|
| April 23, 2025 |
Exhibit 10.1 EXECUTION VERSION FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Agreement”), dated as of April 17, 2025 (the “Fourth Amendment Effective Date”), is entered into among AMEDISYS, INC., a Delaware corporation (the “Company”), AMEDISYS HOLDING, L.L.C., a Louisiana limited liability company (“Amedisys Holding |
|
| April 23, 2025 |
AMEDISYS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS Exhibit 99.1 AMEDISYS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS BATON ROUGE, Louisiana (April 23, 2025) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025. Three-Month Periods Ended March 31, 2025 and 2024 •Net service revenue increased $23.4 million to $594.8 million compared to $571.4 million in 2024. •Net income attributable t |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 17, 2025 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporation |
|
| April 23, 2025 |
1 Amedisys First Quarter 2025 Earnings Release Supplemental Slides April 23, 2025 EXHBIT 99. |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-2 |
|
| February 27, 2025 |
Mutual Separation Agreement and General Release by and between Amedisys, Inc. and Michael P. North Exhibit 10.31 SEPARATION AGREEMENT AND GENERAL RELEASE This SEPARATION AGREEMENT AND GENERAL RELEASE (“Agreement”) hereby is made and entered into by and between Michael P. North (“Executive”) and Amedisys, Inc. (the “Company” or “Amedisys” and together with Executive, collectively the “Parties” and individually a “Party”), and to and for the benefit of the stockholders, directors, officers, succe |
|
| February 27, 2025 |
Exhibit 10.33 December 18, 2023 Jennifer Griffin Re: Accelerated Payments and Potential Repayment Obligations Dear Jennifer: This letter agreement (the “Letter Agreement”) memorializes your agreement and understanding with Amedisys, Inc. (the “Company”) regarding certain accelerated payments and vesting in connection with the anticipated completion of the merger contemplated by the Merger Agreemen |
|
| February 27, 2025 |
Exhibit 10.35 December 24, 2024 Jennifer Griffin Re: Accelerated Payments and Potential Repayment Obligations Dear Jennifer: This letter agreement (the “Letter Agreement”) memorializes your agreement and understanding with Amedisys, Inc. (the “Company”) regarding certain accelerated payments and vesting in connection with the anticipated completion of the merger contemplated by the Merger Agreemen |
|
| February 27, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES CORPORATIONS COMPASSIONATE CARE HOSPICE GROUP, INC., a Florida corporation COMPASSIONATE CARE HOSPICE OF CENTRAL FLORIDA, INC., a Florida corporation COMPASSIONATE CARE HOSPICE OF LAKE AND SUMTER, INC., a Florida corporation COMPASSIONATE CARE HOSPICE OF MIAMI DADE AND THE FLORIDA KEYS, INC., a Florida corporation GUARDIAN HEALTH CARE, INC., a Texas corporation GU |
|
| February 27, 2025 |
Limited Good Reason Waiver, by and between the Company and Nick Muscato, dated November 5, 2024 Exhibit 10.39 LIMITED GOOD REASON WAIVER Reference is made to that certain Agreement and Plan of Merger by an among UnitedHealth Group Incorporated (“United”), Aurora Holdings Merger Sub Inc. and Amedisys, Inc. (the “Merger Agreement”), dated as of June 26, 2023, pursuant to which, upon and subject to the completion of the transactions contemplated by the Merger Agreement, the Company will become |
|
| February 27, 2025 |
Bonus Repayment Agreement, by and between the Company and Jennifer Griffin, dated November 5, 2024 Exhibit 10.38 BONUS REPAYMENT AGREEMENT This BONUS REPAYMENT AGREEMENT (the “Agreement”) is between Amedisys, Inc. a Delaware corporation, including any successor or assign (the “Company”), and Jennifer Guckert Griffin (“Executive”). RECITALS WHEREAS, reference is made to that certain Agreement and Plan of Merger by and among UnitedHealth Group Incorporated (“UnitedHealth Group”), Aurora Holdings |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, INC. |
|
| February 27, 2025 |
Exhibit 10.34 December 24, 2024 Richard Ashworth Re: Accelerated Payments and Potential Repayment Obligations Dear Richard: This letter agreement (the “Letter Agreement”) memorializes your agreement and understanding with Amedisys, Inc. (the “Company”) regarding certain accelerated payments and vesting in connection with the anticipated completion of the merger contemplated by the Merger Agreement |
|
| February 27, 2025 |
Insider Trading Compliance Policy Exhibit 19.1 Amedisys, Inc. Amended and Restated Insider Trading Compliance Policy This Policy concerns the handling of material, nonpublic information relating to Amedisys, Inc. (“Amedisys,” the “Company,” or “we”) or other companies with which we deal and with the buying and selling of stock and other securities of Amedisys and such other companies. For purposes of this Policy, each Amedisys emp |
|
| February 27, 2025 |
Bonus Repayment Agreement, by and between the Company and Nick Muscato, dated November 5, 2024 Exhibit 10.37 BONUS REPAYMENT AGREEMENT This BONUS REPAYMENT AGREEMENT (the “Agreement”) is between Amedisys, Inc. a Delaware corporation, including any successor or assign (the “Company”), and Nick Muscato (“Executive”). RECITALS WHEREAS, reference is made to that certain Agreement and Plan of Merger by and among UnitedHealth Group Incorporated (“UnitedHealth Group”), Aurora Holdings Merger Sub I |
|
| February 27, 2025 |
Bonus Repayment Agreement, by and between the Company and Scott G. Ginn, dated November 5, 2024 Exhibit 10.36 BONUS REPAYMENT AGREEMENT This BONUS REPAYMENT AGREEMENT (the “Agreement”) is between Amedisys, Inc. a Delaware corporation, including any successor or assign (the “Company”), and Scott Ginn (“Executive”). RECITALS WHEREAS, reference is made to that certain Agreement and Plan of Merger by and among UnitedHealth Group Incorporated (“UnitedHealth Group”), Aurora Holdings Merger Sub Inc |
|
| February 27, 2025 |
Limited Good Reason Waiver, by and between the Company and Jennifer Griffin, dated June 26, 2023 Exhibit 10.32 LIMITED GOOD REASON WAIVER Reference is made to that certain Agreement and Plan of Merger by an among UnitedHealth Group Incorporated (“United”), Aurora Holdings Merger Sub Inc. and Amedisys, Inc. (the “Merger Agreement”), dated as of June 26, 2023, pursuant to which, upon and subject to the completion of the transactions contemplated by the Merger Agreement, the Company will become |
|
| February 26, 2025 |
amed4q24ecsupplementalsl 1 Amedisys Fourth Quarter 2024 Earnings Release Supplemental Slides February 26th, 2025 Exhibit 99. |
|
| February 26, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 26, 2025 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporati |
|
| February 26, 2025 |
AMEDISYS REPORTS FOURTH QUARTER AND YEAR END 2024 FINANCIAL RESULTS Exhibit 99.1 AMEDISYS REPORTS FOURTH QUARTER AND YEAR END 2024 FINANCIAL RESULTS BATON ROUGE, Louisiana (February 26, 2025) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2024. Three-Month Periods Ended December 31, 2024 and 2023 •Net service revenue increased $27.3 million to $598.1 million compared to $570.8 million in |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2025 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3131700 (State or other jurisdiction of incorporation |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation o |
|
| December 27, 2024 |
Exhibit 10.1 UnitedHealth Group Incorporated UnitedHealth Group Center 9900 Bren Road East Minnetonka, MN 55343 Aurora Holdings Merger Sub Inc. UnitedHealth Group Center 9900 Bren Road East Minnetonka, MN 55343 Amedisys, Inc. 3854 American Way, Suite A Baton Rouge, LA 70816 Re: Merger Agreement Waivers This waiver letter (this “Waiver”), dated as of December 26, 2024, is executed by Amedisys, Inc. |
|
| December 27, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2024 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3131700 (State or other jurisdiction of incorporati |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS |
|
| November 7, 2024 |
Third Amendment to the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan Exhibit 10.1 THIRD AMENDMENT TO THE AMEDISYS, INC. 2018 OMNIBUS INCENTIVE COMPENSATION PLAN This Third Amendment (this “Amendment”) to the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan, as amended (the “Plan”), is entered into this 31st day of July, 2024, by the Compensation Committee of the Board of Directors (the “Committee”) of Amedisys, Inc. (the “Company”), as authorized pursuant to |
|
| November 6, 2024 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 6, 2024 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporatio |
|
| November 6, 2024 |
AMEDISYS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Exhibit 99.1 AMEDISYS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS BATON ROUGE, Louisiana (November 6, 2024) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024. Three-Month Periods Ended September 30, 2024 and 2023 •Net service revenue increased $31.5 million to $587.7 million compared to $556.2 million in 2023. •Net i |
|
| November 6, 2024 |
1 Amedisys Third Quarter 2024 Earnings Release Supplemental Slides November 6th, 2024 EXHIBIT 99. |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2024 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, INC |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 24, 2024 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporation o |
|
| July 24, 2024 |
1 Amedisys Second Quarter 2024 Earnings Release Supplemental Slides July 24th, 2024 EXHIBIT 99. |
|
| July 24, 2024 |
AMEDISYS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Exhibit 99.1 AMEDISYS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS BATON ROUGE, Louisiana (July 24, 2024) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 •Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023. •Net income attribu |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3131700 (State or other jurisdiction of incorporation) |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1 ) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fil |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, IN |
|
| April 24, 2024 |
1 Amedisys First Quarter 2024 Earnings Release Supplemental Slides April 24th, 2024 Exhibit 99. |
|
| April 24, 2024 |
AMEDISYS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Exhibit 99.1 AMEDISYS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS BATON ROUGE, Louisiana (April 24, 2024) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 ◦Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 24, 2024 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporation |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3131700 (State or other jurisdiction of incorporation) |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, INC. |
|
| February 22, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES CORPORATIONS COMPASSIONATE CARE HOSPICE GROUP, INC., a Florida corporation COMPASSIONATE CARE HOSPICE OF CENTRAL FLORIDA, INC., a Florida corporation COMPASSIONATE CARE HOSPICE OF LAKE AND SUMTER, INC., a Florida corporation COMPASSIONATE CARE HOSPICE OF MIAMI DADE AND THE FLORIDA KEYS, INC., a Florida corporation GUARDIAN HEALTH CARE, INC., a Texas corporation GU |
|
| February 22, 2024 |
Limited Good Reason Waiver, by and between the Company and Richard Ashworth, dated June 26, 2023 Exhibit 10.31 LIMITED GOOD REASON WAIVER Reference is made to that certain Agreement and Plan of Merger by an among UnitedHealth Group Incorporated (“United”), Aurora Holdings Merger Sub Inc. and Amedisys, Inc. (the “Merger Agreement”), dated as of June 26, 2023, pursuant to which, upon and subject to the completion of the transactions contemplated by the Merger Agreement, the Company will become |
|
| February 22, 2024 |
Exhibit 10.33 December 18, 2023 Richard Ashworth Re: Accelerated Payments and Potential Repayment Obligations Dear Richard: This letter agreement (the “Letter Agreement”) memorializes your agreement and understanding with Amedisys, Inc. (the “Company”) regarding certain accelerated payments and vesting in connection with the anticipated completion of the merger contemplated by the Merger Agreement |
|
| February 22, 2024 |
Amedisys, Inc. Policy for the Recovery of Erroneously Awarded Compensation Exhibit 97.1 AMEDISYS, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1.Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay, return, or forfeit Erroneously Awarded Compensation to the Company. This Policy shall be interpreted to comply with Rule 10D-1 promulgated under the Securities Exchange Act of 1934, as a |
|
| February 22, 2024 |
Exhibit 10.34 December 18, 2023 Adam Holton Re: Accelerated Payments and Potential Repayment Obligations Dear Adam: This letter agreement (the “Letter Agreement”) memorializes your agreement and understanding with Amedisys, Inc. (the “Company”) regarding certain accelerated payments and vesting in connection with the anticipated completion of the merger contemplated by the Merger Agreement, dated |
|
| February 22, 2024 |
Limited Good Reason Waiver, by and between the Company and Scott G. Ginn, dated June 26, 2023 Exhibit 10.32 LIMITED GOOD REASON WAIVER Reference is made to that certain Agreement and Plan of Merger by an among UnitedHealth Group Incorporated (“United”), Aurora Holdings Merger Sub Inc. and Amedisys, Inc. (the “Merger Agreement”), dated as of June 26, 2023, pursuant to which, upon and subject to the completion of the transactions contemplated by the Merger Agreement, the Company will become |
|
| February 21, 2024 |
1 Amedisys Fourth Quarter 2023 Earnings Release Supplemental Slides February 21st, 2024 Exhibit 99. |
|
| February 21, 2024 |
AMEDISYS REPORTS FOURTH QUARTER AND YEAR-END 2023 FINANCIAL RESULTS Exhibit 99.1 AMEDISYS REPORTS FOURTH QUARTER AND YEAR-END 2023 FINANCIAL RESULTS BATON ROUGE, Louisiana (February 21, 2024) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 ◦Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2 |
|
| February 21, 2024 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 21, 2024 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporati |
|
| February 13, 2024 |
AMED / Amedisys, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 14)* Name of issuer: Amedisys Inc Title of Class of Securities: Common Stock CUSIP Number: 023436108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 12, 2024 |
AMED / Amedisys, Inc. / Flynn James E Passive Investment SC 13G/A 1 e619240sc13ga-amedisys.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Amedisys, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 023436108 (CUSIP Number) December 31, 202 |
|
| February 8, 2024 |
AMED / Amedisys, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Amedisys, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 023436108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS |
|
| October 24, 2023 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 24, 2023 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporatio |
|
| October 24, 2023 |
AMEDISYS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS Exhibit 99.1 AMEDISYS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS BATON ROUGE, Louisiana (October 24, 2023) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2023. Three-Month Periods Ended September 30, 2023 and 2022 ◦Net service revenue decreased $1.8 million to $556.2 million compared to $558.0 million in 2022. Prior y |
|
| October 24, 2023 |
1 Amedisys Third Quarter 2023 Earnings Release Supplemental Slides October 24th, 2023 Exhibit 99. |
|
| September 8, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3131700 (State or other jurisdiction of incorporati |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Sta |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3131700 (State or other jurisdiction of incorporati |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2023 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or |
|
| August 10, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| July 31, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| July 31, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Amedisys, Inc. |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, INC |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 26, 2023 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporation o |
|
| July 26, 2023 |
AMEDISYS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Exhibit 99.1 AMEDISYS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS BATON ROUGE, Louisiana (July 26, 2023) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2023. Three-Month Periods Ended June 30, 2023 and 2022 ◦Net service revenue decreased $4.9 million to $553.0 million compared to $557.9 million in 2022. ◦Net loss attributab |
|
| July 26, 2023 |
amed2q23ecsupplementalsl 1 Amedisys Second Quarter 2023 Earnings Release Supplemental Slides July 26th, 2023 Exhibit 99. |
|
| July 6, 2023 |
AMED / Amedisys Inc. / JPMORGAN CHASE & CO - FILING AMEDISYS, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* AMEDISYS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 023436108 (CUSIP Number) June 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 26, 2023 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among UNITEDHEALTH GROUP INCORPORATED, AURORA HOLDINGS MERGER SUB INC. and AMEDISYS, INC. dated as of June 26, 2023 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.1. The Merger 2 Section 1.2. Closing 2 Section 1.3. Effective Time 2 Section 1.4. Effects of the Transaction 2 ARTICLE II DIRECTORS AND OFFICERS; ORGANIZATIONAL |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 26, 2023 |
Amedisys and Optum to Combine, Advancing Value-Based Care for Patients Exhibit 99.1 Amedisys and Optum to Combine, Advancing Value-Based Care for Patients BATON ROUGE, La. – June 26, 2023 – Amedisys (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care, and Optum, a diversified health services company, have agreed to combine. The agreement calls for the acquisition of Amedisys’s outstanding common stock in an all-cash transaction for $101 pe |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 26, 2023 |
Exhibit 10.1 TERMINATION AGREEMENT This TERMINATION AGREEMENT (this “Agreement”), dated as of June 26, 2023, is made and entered into by and between Option Care Health, Inc., a Delaware corporation (“OPCH”), Uintah Merger Sub, Inc., a wholly owned subsidiary of OPCH and a Delaware corporation (“OPCH Merger Sub”), and Amedisys, Inc., a Delaware corporation (“Amedisys”, together with OPCH and OPCH M |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3131700 (State or other jurisdiction of incorporation) |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3131700 (State or other jurisdiction of incorporation) |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3131700 (State or other jurisdiction of incorporation) |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 OPTION CARE HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-11993 (Commission File Number |
|
| June 13, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 8, 2023 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction (IRS Employer of in |
|
| June 5, 2023 |
Filed by Amedisys, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is a transcript of a pre-recorded video recorded by Amedisys, Inc. and distributed to employees of Amedisys, Inc. on June 5, 2023. Richard Ashworth, C |
|
| June 5, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3131700 (State or other jurisdiction of incorporation) ( |
|
| June 5, 2023 |
Filed by Amedisys, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 AMEDISYS ANNOUNCES RECEIPT OF UNSOLICITED PROPOSAL FROM OPTUM Amedisys Board Determines Optum Proposal Could Reasonably be Expected to Result in a Superior Proposal Amedisys Engaging |
|
| June 5, 2023 |
Exhibit 99.1 AMEDISYS ANNOUNCES RECEIPT OF UNSOLICITED PROPOSAL FROM OPTUM Amedisys Board Determines Optum Proposal Could Reasonably be Expected to Result in a Superior Proposal Amedisys Engaging in Discussions with Optum BATON ROUGE, La., June 5, 2023 – Amedisys, Inc. (“Amedisys” or the “Company”) (NASDAQ: AMED) today announced that on May 26, 2023, the Company received an unsolicited proposal fr |
|
| June 5, 2023 |
Filed by Amedisys, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Amedisys Employee Letter To: All Amedisys Employees From: Richard Ashworth Subject: Video Message From CEO Richard Ashworth Dear Colleagues: Today we issued this press release announ |
|
| May 26, 2023 |
Filed by Option Care Health, Inc. Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is a screenshot of an updated web page on the website hosted at www.optioncarehealthamedisys.com in connection with the proposed merger of O |
|
| May 26, 2023 |
Filed by Amedisys, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is a screenshot of a new web page added to the website hosted at www.optioncarehealthamedisys.com in connection with the proposed merger of Option Car |
|
| May 18, 2023 |
Filed by Amedisys, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is a screenshot of a new web page added to an internal website hosted by Amedisys, Inc. for its employees in connection with the proposed merger of Op |
|
| May 18, 2023 |
AMED / Amedisys Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| May 17, 2023 |
Filed by Option Care Health, Inc. Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is an excerpt from Option Care Health Inc.’s webcast of its 2023 annual meeting held on May 17, 2023: Our Q1 2023 results continue to demons |
|
| May 15, 2023 |
Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following are screenshots of new web pages added to the website hosted at www.optioncarehealthamedisys.com in connection with the proposed merger of O |
|
| May 15, 2023 |
Filed by Amedisys, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following are screenshots of new web pages added to the website hosted at www.optioncarehealthamedisys.com in connection with the proposed merger of Option Care |
|
| May 15, 2023 |
Filed by Amedisys, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is a presentation by Amedisys, Inc. posted to a website hosted at www.optioncarehealthamedisys.com in connection with the proposed merger of Option Ca |
|
| May 15, 2023 |
Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is a presentation by Option Care Health, Inc. posted to a website hosted at www.optioncarehealthamedisys.com in connection with the proposed |
|
| May 10, 2023 |
Filed by Option Care Health, Inc. Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is a transcript of a presentation by Option Care Health, Inc. at the BofA Securities Health Care Conference 2023. Option Care Health BofA Se |
|
| May 5, 2023 |
Filed by Option Care Health, Inc. 425 1 tm2314202d13425.htm 425 Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is a transcript of an employee townhall held by Option Care Health, Inc. on May 4, 2023. Welcome to you all! I |
|
| May 4, 2023 |
Option Care Health and Amedisys Transaction May 03, 2023 425 1 tm2314202d12425.htm 425 Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is a transcript of an investor call held by Option Care Health, Inc. and Amedisys, Inc. on May 3, 2023. Option |
|
| May 4, 2023 |
Exhibit 2.1 EQUITY PURCHASE AGREEMENT by and among ASSOCIATED HOME CARE, L.L.C., AMEDISYS PERSONAL CARE, LLC, AMEDISYS, INC. and HOUSEWORKS HOLDINGS, LLC Dated as of February 10, 2023 Table of Contents ARTICLE 1 PURCHASE AND SALE OF INTERESTS 1 1.01 Purchase and Sale of Interests 1 1.02 Payments at the Closing 1 1.03 Calculation of Closing and Final Consideration 2 1.04 The Closing 4 ARTICLE 2 CON |
|
| May 4, 2023 |
Filed by Option Care Health, Inc. Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following are screenshots of a website hosted at www.optioncarehealthamedisys.com in connection with the proposed merger of Option Care Health, Inc. a |
|
| May 4, 2023 |
Separation Agreement and General Release by and between Amedisys, Inc. and Christopher T. Gerard Exhibit 10.1 Unless and until this Agreement is “Effective,” it, and the discussions about entering into such an agreement, are Confidential Under F.R.E. 408 and its state counterparts and not admissible. SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (“Agreement”) is entered into by and effective between Amedisys, Inc. (the “Company”) and Christopher T. Ger |
|
| May 4, 2023 |
Filed by Amedisys, Inc.. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following are screenshots of a website hosted at www.optioncarehealthamedisys.com in connection with the proposed merger of Option Care Health, Inc. and Amedis |
|
| May 4, 2023 |
Filed by Amedisys, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following are social media posts from Amedisys, Inc. in connection with the proposed merger of Option Care Health, Inc. and Amedisys, Inc. Twitter: https://twit |
|
| May 4, 2023 |
Filed by Option Care Health, Inc. Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is an email communication made by Option Care Health, Inc. to Amedisys, Inc.’s employees on May 4, 2023. Amedisys Team, On behalf of my coll |
|
| May 4, 2023 |
Exhibit 10.2 EXECUTION VERSION THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Agreement”), dated as of March 10, 2023 (the “Third Amendment Effective Date”), is entered into among AMEDISYS, INC., a Delaware corporation (the “Company”), AMEDISYS HOLDING, L.L.C., a Louisiana limited liability company (“Amedisys Holding”; |
|
| May 4, 2023 |
Filed by Option Care Health, Inc. Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following LinkedIn and Facebook posts were issued by Option Care Health, Inc. on May 3, 2023. LinkedIn Post 05.03.2023 Facebook Post 05.03.2023 No Off |
|
| May 4, 2023 |
Option Care Health and Amedisys Transaction May 03, 2023 Filed by Amedisys, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Option Care Health, Inc. Commission File No.: 000-11993 Explanatory Note: The following is a transcript of an investor call held by Amedisys, Inc. and Option Care Health, Inc. on May 3, 2023. Option Care Health and Amedisys Tran |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, IN |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3131700 (State or other jurisdiction of incorporation) (I |
|
| May 3, 2023 |
amed1q23ecsupplementalsl 1 Amedisys First Quarter 2023 Earnings Release Supplemental Slides May 3rd, 2023 Exhibit 99. |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 3, 2023 OPTION CARE HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-11993 05-0489664 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 3, 2023 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or |
|
| May 3, 2023 |
AMEDISYS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES 2023 GUIDANCE Exhibit 99.1 AMEDISYS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES 2023 GUIDANCE BATON ROUGE, Louisiana (May 3, 2023) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2023. Three-Month Periods Ended March 31, 2023 and 2022 ◦Net service revenue increased $11.1 million to $556.4 million compared to $545.3 million in 2022. ◦Ne |
|
| May 3, 2023 |
425 1 tm2314392d6425.htm 425 Filed by Amedisys, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 1 | P a g e Amedisys Employee FAQ 1. What does this transaction mean for Amedisys employees? • There is so much to be excited about in bringing Amedisys |
|
| May 3, 2023 |
Filed by Amedisys, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 1 | P a g e Amedisys Employee Letter To: All Amedisys Employees From: Richard Ashworth Subject: Amedisys to Combine with Option Care Health Amedisys Team, Today marks the beginning o |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3131700 (State or other jurisdiction of incorporation) (I |
|
| May 3, 2023 |
Filed by Option Care Health, Inc. Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is an email communication made by Option Care Health, Inc. to investors and analysts on May 3, 2023. SUBJECT: Option Care Health Q1 Earnings |
|
| May 3, 2023 |
Filed by Option Care Health, Inc. Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is an email communication made by Option Care Health, Inc. to its employees on May 3, 2023. Subject: Option Care Health to Combine with Amed |
|
| May 3, 2023 |
Filed by Amedisys, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Combining to Create a Leading, Independent Platform for Home and Alternate Site Care Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, |
|
| May 3, 2023 |
Filed by Amedisys, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 1 | P a g e Amedisys Social Media Posts Below are social media posts for Amedisys to leverage across platforms in connection with the announcement. The microsite link will include th |
|
| May 3, 2023 |
Investor Presentation May 3, 2023 + Exhibit 99.2 Investor Presentation May 3, 2023 + + Disclaimer 2 No Offer or Solicitation This communication relates to the proposed merger (the “proposed transaction”) between Option Care Health, Inc . (“Option Care Health”) and Amedisys, Inc . (“Amedisys”) . This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to sell or the solicitation o |
|
| May 3, 2023 |
Exhibit 99.1 Option Care Health and Amedisys to Combine Creating a Leading, Independent Platform for Home and Alternate Site Care All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, Payers, and Care Teams Increases Access to High Quality Care for Communities Across the U.S. through a Unique National Clinical Platform Comprehensive |
|
| May 3, 2023 |
Filed by Option Care Health, Inc. Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is an email communication from Option Care Health, Inc. to health care providers. [NAME], Thank you for reaching out. As you may have seen, |
|
| May 3, 2023 |
Filed by Option Care Health, Inc. Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following infographic is being filed in connection with the proposed merger of Option Care Health, Inc. and Amedisys, Inc. |
|
| May 3, 2023 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among OPTION CARE HEALTH, INC., UINTAH MERGER SUB, INC. and AMEDISYS, INC. dated as of May 3, 2023 TABLE OF CONTENTS Page Article I THE MERGER 2 Section 1.1. The Merger 2 Section 1.2. Closing 2 Section 1.3. Effective Time 2 Section 1.4. Effects of the Transaction 2 Section 1.5. Intended Tax Treatment 2 Article II DIRECTORS AND OFFIC |
|
| May 3, 2023 |
Filed by Option Care Health, Inc. Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following are materials provided by Option Care Health, Inc. to its employees on May 3, 2023. 1. Why are Option Care Health and Amedisys combining? · |
|
| May 3, 2023 |
Filed by Option Care Health, Inc. Filed by Option Care Health, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Amedisys, Inc. Commission File No.: 000-24260 Explanatory Note: The following is an email communication from Option Care Health, Inc. to health systems, clinics and customers. [NAME], Thank you for reaching out. As you |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 27, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2023 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or o |
|
| March 13, 2023 |
EX-99.1 Exhibit 99.1 Amedisys Board Appoints Richard Ashworth as New President and Chief Executive Officer Healthcare leader brings wealth of operational and business development experience BATON ROUGE, La., March 13, 2023 – Amedisys, Inc. (NASDAQ: AMED), the leading provider of quality home health, hospice, and high-acuity care services, today announced that its Board of Directors has named Richa |
|
| February 16, 2023 |
Exhibit 10.27 AMENDMENT NO. 1 TO AMEDISYS HOLDING, L.L.C. AMENDED AND RESTATED SEVERANCE PLAN FOR EXECUTIVE OFFICERS THIS AMENDMENT NO. 1 TO AMEDISYS HOLDING, L.L.C. AMENDED AND RESTATED SEVERANCE PLAN FOR EXECUTIVE OFFICERS (this “Amendment”) is made as of the 21st day of November, 2022 (the “Effective Date”), by Amedisys Holding, L.L.C., a Louisiana limited liability company (the “Company”). W I |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, INC. |
|
| February 16, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES CORPORATIONS COMPASSIONATE CARE HOSPICE GROUP, INC., a Florida corporation COMPASSIONATE CARE HOSPICE OF CENTRAL FLORIDA, INC., a Florida corporation COMPASSIONATE CARE HOSPICE OF LAKE AND SUMTER, INC., a Florida corporation COMPASSIONATE CARE HOSPICE OF MIAMI DADE AND THE FLORIDA KEYS, INC., a Florida corporation GUARDIAN HEALTH CARE, INC., a Texas corporation GU |
|
| February 15, 2023 |
Exhibit 99.1 AMEDISYS REPORTS FOURTH QUARTER AND YEAR-END 2022 FINANCIAL RESULTS, ISSUES 2023 GUIDANCE, ANNOUNCES SALE OF ITS PERSONAL CARE LINE OF BUSINESS AND SIGNS INNOVATIVE PALLIATIVE CARE AT HOME PARTNERSHIP WITH BLUECROSS BLUESHIELD OF TENNESSEE BATON ROUGE, Louisiana (February 15, 2023) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year |
|
| February 15, 2023 |
Exhibit 99.3 Amedisys Announces Divestiture of its Personal Care Division Amedisys and HouseWorks form Care Coordination Partnership to Enhance Amedisys Personal Care Network BATON ROUGE, LA., February 15, 2023 - Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care, today announces that it has signed a definitive agreement to divest its Personal Care divis |
|
| February 15, 2023 |
1 Amedisys Fourth Quarter 2022 Earnings Call Supplemental Slides February 16th, 2023 Exhibit 99. |
|
| February 15, 2023 |
Exhibit 99.4 Amedisys Partners with BlueCross BlueShield of Tennessee to Provide Palliative Care at Home to Members Program focuses on enhancing quality of life for members in Middle Tennessee in their homes Nashville, Tenn. – February 15, 2023 – Today, Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care, announced a new agreement with BlueCross BlueShiel |
|
| February 15, 2023 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 10, 2023 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporati |
|
| February 14, 2023 |
EX-99.I 2 d474628dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. |
|
| February 14, 2023 |
to Schedule 13G Joint Filing Agreement EX-99.II 3 d474628dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2023 in connection with their beneficial ownership of Amedisys, Inc. Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute the Schedule 13G to which this |
|
| February 14, 2023 |
AMED / Amedisys Inc / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A 1 d474628dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #1 Under the Securities and Exchange Act of 1934 Amedisys, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 023436108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 9, 2023 |
AMED / Amedisys Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0227-amedisysinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Amedisys Inc. Title of Class of Securities: Common Stock CUSIP Number: 023436108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule |
|
| February 9, 2023 |
Amedisys Board of Directors Authorizes $100 Million Stock Repurchase Program Exhibit 99.1 Amedisys Board of Directors Authorizes $100 Million Stock Repurchase Program BATON ROUGE, La., February 9, 2023 – Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, today announced that its Board of Directors has authorized a stock repurchase program, under which the Company may repurchase up to $100 million of its ou |
|
| February 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or |
|
| February 6, 2023 |
AMED / Amedisys Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Amedisys, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 023436108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| January 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 9, 2023 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporation |
|
| January 9, 2023 |
1 AMEDISYS OVERVIEW Exhibit 99.1 2 The next decade is the peak of senior population growth, particularly for high-support elderly 2015 16 65m 6 6 8 57m 15 18 7 7 10 2020 20 11 7 8 13 2025E 20 19 15 9 11 2030E 65 to 69 years 70 to 74 years 75 to 79 years 85+ years 80 to 84 years47m (15% of population) 74m (20% of population) 17 1. Does not take into account any population impact due to COVID 2020-2 |
|
| January 6, 2023 |
AMED / Amedisys Inc / JPMORGAN CHASE & CO - FILING AMEDISYS, INC. Passive Investment SC 13G 1 AMEDISYSINC.htm FILING AMEDISYS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AMEDISYS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 023436108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| December 16, 2022 |
Composite of By-Laws of the Company inclusive of all amendments through December 14, 2022 Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF AMEDISYS, INC. Incorporated under the Laws of the State of Delaware (As amended December 14, 2022) ARTICLE I. OFFICES AND RECORDS SECTION 1.1. Delaware Office. The principal office of the Corporation in the State of Delaware shall be located in the City of Wilmington, County of New Castle. SECTION 1.2. Other Offices. The Corporation may have such other o |
|
| December 16, 2022 |
Amended and Restated By-Laws (marked) Exhibit 3.2 COMPOSITE AMENDED AND RESTATED BY-LAWS OF AMEDISYS, INC. Incorporated under the Laws of the State of Delaware ( Inclusive of Amendments Dated October 20 As amended December 14, 2021 2022) ARTICLE I. OFFICES AND RECORDS SECTION 1.1. Delaware Office. The principal office of the Corporation in the State of Delaware shall be located in the City of Wilmington, County of New Castle. SECTION |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation o |
|
| December 13, 2022 |
Amedisys Completes Home Health Joint Venture with the University of Arkansas for Medical Sciences EX-99.1 Exhibit 99.1 Amedisys Completes Home Health Joint Venture with the University of Arkansas for Medical Sciences LITTLE ROCK, Ark. and NASHVILLE, Tenn., December 13, 2022 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, has closed on its joint venture with the University of Arkansas for Medical Sciences |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation o |
|
| November 22, 2022 |
Amedisys Names Scott Ginn Acting Chief Operating Officer Exhibit 99.1 Amedisys Names Scott Ginn Acting Chief Operating Officer BATON ROUGE, La., November 22, 2022 (GLOBE NEWSWIRE) ? Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, names Scott Ginn, Executive Vice President and Chief Financial Officer, its Acting Chief Operating Officer, effective immediately. ?I am delighted to have Scott Gin |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation o |
|
| November 18, 2022 |
Amedisys Confirms Full Year Guidance EX-99.1 Exhibit 99.1 Amedisys Confirms Full Year Guidance Baton Rouge, LA (November 17, 2022) — Today, the Board of Directors of Amedisys, Inc. (NASDAQ: AMED) announced a leadership change that President and Chief Executive Officer, Chris Gerard, will leave the company effective November 17, 2022, and Paul Kusserow, Chair of the Board of Directors will take over as Chief Executive Officer until a |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation o |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation o |
|
| November 17, 2022 |
Amedisys Announces CEO Departure Paul Kusserow returns as Chairman and CEO Exhibit 99.1 Amedisys Announces CEO Departure Paul Kusserow returns as Chairman and CEO Baton Rouge, LA (November 17, 2022) ? Today, the Board of Directors of Amedisys, Inc. (NASDAQ: AMED) announced that President and Chief Executive Officer, Chris Gerard, will leave the company effective November 17, 2022. Paul Kusserow, Chairman of the Board of Directors, will serve as Chairman and CEO until a r |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS |
|
| October 27, 2022 |
Exhibit 10.1 MUTUAL SEPARATION AGREEMENT AND GENERAL RELEASE This MUTUAL SEPARATION AGREEMENT AND GENERAL RELEASE (?Agreement?) hereby is made and entered into by and between David L. Kemmerly (?Executive?) and Amedisys, Inc. (the ?Company? or ?Amedisys? and together with Executive, collectively the ?Parties,? and individually a ?Party?), and to and for the benefit of the stockholders, directors, |
|
| October 26, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 26, 2022 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporatio |
|
| October 26, 2022 |
AMEDISYS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND UPDATES 2022 GUIDANCE Exhibit 99.1 AMEDISYS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND UPDATES 2022 GUIDANCE BATON ROUGE, Louisiana (October 26, 2022) ? Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2022. Three-Month Periods Ended September 30, 2022 and 2021 ?Net service revenue increased $4.5 million to $558.0 million compared to $553. |
|
| October 26, 2022 |
1 Amedisys Third Quarter 2022 Earnings Call Supplemental Slides October 27th, 2022 Exhibit 99. |
|
| October 21, 2022 |
Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or |
|
| September 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation |
|
| August 2, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or o |
|
| August 2, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: August 2, 2022 Dana Schroering, Contessa [email protected] Tildy La Farge, Mount Sinai Health System [email protected] Mount Sinai Health System Partners with Contessa to Create Mount Sinai at Home, a Home-Based Care Continuum Mount Sinai at Home provides home health, hospitalization at home, rehabilitation at home and palliative |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, INC |
|
| July 27, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 27, 2022 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporation o |
|
| July 27, 2022 |
1 Amedisys Second Quarter 2022 Earnings Call Supplemental Slides July 28th, 2022 Exhibit 99. |
|
| July 27, 2022 |
AMEDISYS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND UPDATES 2022 REVENUE GUIDANCE Exhibit 99.1 AMEDISYS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND UPDATES 2022 REVENUE GUIDANCE BATON ROUGE, Louisiana (July 27, 2022) ? Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2022. Three-Month Periods Ended June 30, 2022 and 2021 ?Net service revenue decreased $6.3 million to $557.9 million compared to $564.2 mil |
|
| June 24, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: June 24, 2022 Dana Schroering, Contessa (502) 727-0193, [email protected] Memorial Hermann [email protected] Memorial Hermann and Contessa Partner to Provide Patients New At-Home Care Options This partnership gives patients options of where to receive inpatient, rehabilitation, and palliative care Houston, TX and Nashville |
|
| June 24, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or or |
|
| June 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or org |
|
| June 9, 2022 |
Exhibit 99.2 FOR IMMEDIATE RELEASE Contacts: June 9, 2022 Dana Schroering, Contessa (502) 727-0193 [email protected] Julie Smith, Baylor Scott & White Health (940) 765-7560 [email protected] Baylor Scott & White Health and Contessa Announce Partnership to Create New Model of At-Home Care for Patients Partnership will create a continuum of at-home care that encourages patient c |
|
| June 9, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or org |
|
| June 9, 2022 |
Amedisys Releases Inaugural Environmental, Social and Governance (ESG) Report Exhibit 99.1 Amedisys Releases Inaugural Environmental, Social and Governance (ESG) Report BATON ROUGE, La., June 9, 2022 ?Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, has released its first Environmental, Social and Governance (ESG) Report for the year 2021, detailing actions, achievements and goals in each critical area. ?We are i |
|
| June 6, 2022 |
Amedisys William Blair Growth Stock Conference Monday June 6th, 2022 Exhibit 99.1 Introduction: Chris Gerard, President and CEO Chris Gerard is President & Chief Executive Officer of Amedisys (AMED), a publicly traded, leading provider of home health, hospice, palliative, personal care and high-acuity care services with approximately 21,000 employees in 38 states and the District of Columbia, maki |
|
| June 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 6, 2022 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, IN |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 27, 2022 |
Amedisys First Quarter 2022 Earnings Call Supplemental Slides April 28th, 2022 Exhibit 99. |
|
| April 27, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 27, 2022 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporation |
|
| April 27, 2022 |
DEF 14A 1 d299547ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the |
|
| April 27, 2022 |
AMEDISYS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND REAFFIRMS 2022 GUIDANCE Exhibit 99.1 AMEDISYS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND REAFFIRMS 2022 GUIDANCE BATON ROUGE, Louisiana (April 27, 2022) ? Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2022. Three-Month Periods Ended March 31, 2022 and 2021 ? Net service revenue increased $8.2 million to $545.3 million compared to $537.1 million in 2021 |
|
| April 4, 2022 |
Amedisys Completes Acquisition of Evolution Health Exhibit 99.1 Amedisys Completes Acquisition of Evolution Health BATON ROUGE, La., April 4, 2022 ? (GLOBE NEWSWIRE) ? Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, has closed on its acquisition of Evolution Health, LLC, a provider of home health services. Evolution Health, LLC, a division of Envision Healthcare, is doing busin |
|
| April 4, 2022 |
Exhibit 99.2 Amedisys Completes Acquisition of Home Health Assets from AssistedCare Home Health and AssistedCare of the Carolinas BATON ROUGE, La., April 4, 2022 ? (GLOBE NEWSWIRE) ? Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, has closed on its acquisition of certain home health assets from AssistedCare Home Health, Inc., a |
|
| April 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or or |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation o |
|
| February 24, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES CORPORATIONS COMPASSIONATE CARE HOSPICE GROUP, INC., a Florida corporation COMPASSIONATE CARE HOSPICE OF CENTRAL FLORIDA, INC., a Florida corporation COMPASSIONATE CARE HOSPICE OF LAKE AND SUMTER, INC., a Florida corporation COMPASSIONATE CARE HOSPICE OF MIAMI DADE AND THE FLORIDA KEYS, INC., a Florida corporation HI-TECH CARE, INC., a Florida Corporation HOMECARE |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, INC. |
|
| February 24, 2022 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the capital stock of Amedisys, Inc. does not purport to be complete and is qualified in its entirety by reference to our certificate of incorporation, as amended, bylaws, as amended, each of which are incorporated by reference as an exhibit to the |
|
| February 23, 2022 |
Exhibit 99.2 Amedisys Fourth Quarter 2021 Earnings Call Supplemental Slides 1 1 th, February 24 2022 Forward-looking statements This presentation may include forward-looking statements as defined by the Private www.amedisys.com Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a NASD |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation o |
|
| February 23, 2022 |
Exhibit 99.2 FOR IMMEDIATE RELEASE February 23, 2022 CONTACTS: Virginia Mason Franciscan Health (253) 382-3850 [email protected] Dana Schroering, Contessa (502) 727-0193 [email protected] Virginia Mason Franciscan Health Collaborates with Contessa to Bring Hospital-Level Care into Patients? Homes Home Recovery Care gives patients the choice to receive hospital care at home, lo |
|
| February 23, 2022 |
Exhibit 99.1 Amedisys Signs Definitive Agreement to Acquire Home Health Assets from AssistedCare Home Health and AssistedCare of the Carolinas BATON ROUGE, La., February 23, 2022 (GLOBE NEWSWIRE) ? Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, announced today that it has signed a definitive agreement to acquire certain home h |
|
| February 23, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 23, 2022 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporati |
|
| February 23, 2022 |
AMEDISYS REPORTS FOURTH QUARTER AND YEAR END 2021 FINANCIAL RESULTS ISSUES 2022 GUIDANCE Exhibit 99.1 AMEDISYS REPORTS FOURTH QUARTER AND YEAR END 2021 FINANCIAL RESULTS ISSUES 2022 GUIDANCE BATON ROUGE, Louisiana (February 23, 2022) ? Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2021. Three-Month Periods Ended December 31, 2021 and 2020 ? Net service revenue increased $8.6 million to $559.3 million compared |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction |
|
| February 14, 2022 |
to Schedule 13G Joint Filing Agreement Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2022 in connection with their beneficial ownership of Amedisys, Inc. |
|
| February 14, 2022 |
Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser ? Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. |
|
| February 14, 2022 |
AMED / Amedisys Inc / AMERIPRISE FINANCIAL INC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 Amedisys, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 023436108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: This Schedule is fi |
|
| February 9, 2022 |
AMED / Amedisys Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Amedisys Inc. Title of Class of Securities: Common Stock CUSIP Number: 023436108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 4, 2022 |
AMED / Amedisys Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Amedisys, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 023436108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 2, 2022 |
Amedisys Signs Definitive Agreement to Acquire Evolution Health Exhibit 99.1 Amedisys Signs Definitive Agreement to Acquire Evolution Health BATON ROUGE, La., February 2, 2022 (GLOBE NEWSWIRE) ? Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, announced today that it has signed a definitive agreement to acquire Evolution Health, LLC, a division of Envision Healthcare, doing business as Guard |
|
| February 2, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or |
|
| January 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 12, 2022 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporatio |
|
| January 12, 2022 |
Exhibit 99.1 th Amedisys Presentation at the 40 Annual J.P. Morgan Healthcare Conference 1 1 Forward-looking statements This presentation may include forward-looking statements as defined by the Private www.amedisys.com Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a NASDAQ: AMED |
|
| January 10, 2022 |
Amedisys Holding, L.L.C. Severance Plan for Chief Executive Officer Exhibit 10.1 AMEDISYS HOLDING, L.L.C. SEVERANCE PLAN FOR CHIEF EXECUTIVE OFFICER JANUARY 2022 1. Purpose. The purpose of this Amedisys Holding, L.L.C. Severance Plan for the Chief Executive Officer (this ?Plan?) is to provide a fair framework in the event of the termination of employment in certain circumstances for the Chief Executive Officer of the Company. This document supersedes any prior pla |
|
| January 10, 2022 |
Exhibit 99.1 Amedisys Announces Paul Kusserow?s Retirement as Chief Executive Officer and Appoints Chris Gerard as Chief Executive Officer Effective April 15, 2022 Baton Rouge, LA (January 10th, 2022) - Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high acuity care services, today announced that Chairman and Chief Executive Officer (CEO) Paul Kusserow |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or |
|
| November 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation o |
|
| November 10, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE November 10, 2021 CONTACTS: Scott Gilbert, Penn State Health (717)782-1121 [email protected] Dana Schroering, Contessa (502) 727-0193 [email protected] Rachel Borowski, Highmark Health (412) 953-7089 [email protected] Penn State Health Partners with Highmark Health and Contessa to Launch Home Recovery Care, a new At-H |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS |
|
| November 3, 2021 |
Composite of By-Laws of the Company inclusive of all amendments through October 20, 2021 Exhibit 3.2 COMPOSITE BY-LAWS OF AMEDISYS, INC. Incorporated under the Laws of the State of Delaware (Inclusive of Amendments Dated October 20, 2021) ARTICLE I. OFFICES AND RECORDS SECTION 1.1. Delaware Office. The principal office of the Corporation in the State of Delaware shall be located in the City of Wilmington, County of New Castle. SECTION 1.2. Other Offices. The Corporation may have such |
|
| November 2, 2021 |
AMEDISYS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS UPDATES 2021 GUIDANCE Exhibit 99.1 AMEDISYS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS UPDATES 2021 GUIDANCE BATON ROUGE, Louisiana (November 2, 2021) ? Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2021. Three-Month Periods Ended September 30, 2021 and 2020 ? Net service revenue increased $9.4 million to $553.5 million compared to $544.1 m |
|
| November 2, 2021 |
EX-99.2 3 d245311dex992.htm EX-99.2 Amedisys Third Quarter 2021 Earnings Call Supplemental Slides November 3rd, 2021 Exhibit 99.2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks an |
|
| November 2, 2021 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 2, 2021 Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of incorporatio |
|
| October 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2021 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation or |
